in a prospective randomised trial , children of hepatitis b carriers who were 3 months to 11 years of age and negative for all hepatitis b viral markers were randomised to receive ( a ) two doses of 5 micrograms of hepatitis b recombinant dna yeast vaccine ( h-b-vax ii ) at 0 and 1 month ( group i ) , ( b ) three doses of 5 micrograms of h-b-vax ii at 0 , 1 and 6 months ( group ii ) and ( c ) three doses of 10 micrograms of plasma-derived hepatitis b vaccine ( h-b-vax ) ( group iii ) .
C0019163
hepatitis b viral
C0062527
hepatitis b vaccine